NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Technological advances reduce time and increase efficiency for MDD treatmentMALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved multiple proprietary innovations, which significantly advance the patient treatment experience with the NeuroStar TMS (transcranial magnetic stimulation) Therapy System for the treatment of major depressive disorder (MDD) in Japan. The features covered in this approval include

Also on site :